Welcome to our dedicated page for Lexeo Therapeutics SEC filings (Ticker: LXEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lexeo Therapeutics, Inc. filings document a clinical-stage cardiovascular genetic medicine company and its formal disclosures on operations, pipeline progress, governance, and capital resources. Recent 8-K reports furnish financial results, business highlights, corporate presentations, and clinical updates for AAV gene therapy programs including LX2006 and LX2020.
The company’s SEC record also covers Regulation FD materials, CMC and regulatory-update disclosures, leadership transitions, director appointments, compensatory arrangements, and proxy matters for annual stockholder meetings. Its definitive proxy statement addresses board service, committee structure, voting proposals, executive compensation, and other governance information relevant to Lexeo’s public-company oversight.
Lexeo Therapeutics, Inc. director Mette Kirstine Agger received a grant of stock options covering 35,000 shares of common stock. The options have an exercise price of $4.70 per share and expire on June 24, 2036. According to the vesting terms, all 35,000 underlying shares will vest and become exercisable on the earlier of one year after the grant date or the next annual meeting of stockholders, as long as she continues in service through that date. After this grant, she holds stock options for 35,000 shares directly.
Lexeo Therapeutics director Brenda Cooperstone received a grant of stock options covering 35,000 shares of common stock. The options have an exercise price of $4.70 per share and expire on June 24, 2036. All 35,000 underlying shares vest on the earlier of one year after the grant date or the next annual meeting of stockholders, subject to her continuous service, leaving her with 35,000 derivative securities following this award.
Lexeo Therapeutics director Reinaldo M. Diaz received a grant of stock options as equity compensation. He was awarded options to acquire 35,000 shares of common stock at an exercise price of $4.70 per share, with all shares underlying the option scheduled to vest and become exercisable on the earlier of one year after the grant date or the next annual meeting of stockholders, conditioned on his continuous service.
Lexeo Therapeutics director Tolga Tanguler received a new stock option award. The grant covers 35,000 options to buy Lexeo common stock at an exercise price of $4.70 per share and will expire on June 24, 2036.
According to the vesting terms, 100% of the shares underlying the option will vest, and become exercisable, on the earlier of one year after the grant date or the next annual meeting of stockholders, subject to his continuous service. Following this award, he holds 35,000 stock options directly.
Lexeo Therapeutics, Inc. director Timothy Van Hauwermeiren received a grant of stock options covering 35,000 shares of common stock. The options have an exercise price of $4.70 per share and expire on June 24, 2036. All 35,000 underlying shares will vest and become exercisable on the earlier of one year after the grant date or the next annual meeting of stockholders, assuming he continues in service through that date. Following this award, he holds options on 35,000 shares directly.
Lexeo Therapeutics, Inc. director Paula H. Cholmondeley reported receiving a stock option grant covering 35,000 shares of common stock. The option has an exercise price of $4.7000 per share and expires on June 24, 2036. According to the disclosure, all 35,000 underlying shares will vest and become exercisable on the earlier of one year after the grant date or the next annual meeting of stockholders, provided she continues in service through that date.
Lexeo Therapeutics outlined a pivotal development plan for LX2006, its gene therapy for Friedreich ataxia cardiomyopathy. The company has finalized the SUNRISE‑FA 2 pivotal trial protocol and statistical analysis plan intended to support a Biologics License Application under the FDA’s accelerated approval pathway in the first half of 2028.
SUNRISE‑FA 2 is an open-label study in which 13 adults will receive a single high dose of LX2006 at 1.2x1012 vector genomes per kilogram, compared with 13 untreated controls. The primary endpoint is left ventricular mass index at six months, with key secondary cardiac and neurologic measures. Phase I/II data showed mean LVMI reductions of 18% in participants with abnormal baseline LVMI and 28% in a higher-dose subgroup, and LX2006 has generally been well tolerated across 17 treated participants.
Enrollment for the pivotal trial is expected to begin in the second quarter of 2026, with topline data targeted for the second half of 2027. Lexeo also highlighted its CLARITY‑FA natural history study, continued FDA discussions on confirmatory evidence for full approval, progress in its LX2020 program for PKP2 arrhythmogenic cardiomyopathy, and a cash runway that extends into 2028.
Lexeo Therapeutics, Inc. Chief Operating Officer Jose Manuel Otero reported a sale of 1,302 shares of common stock on May 18, 2026 at a weighted average price of $5.074 per share. According to the filing, this sale was made to cover tax obligations arising from the release of restricted stock units.
After the transaction, Otero holds 130,088 shares of Lexeo common stock, which includes 100,621 Restricted Stock Units. The trade was reported as a direct ownership transaction and was executed in multiple trades at prices ranging from $5.06 to $5.11 per share.
Lexeo Therapeutics, Inc. Chief Executive Officer Richard Nolan Townsend reported an open-market sale of 3,342 shares of common stock at a weighted average price of $5.0649 per share on May 18, 2026. The footnotes state this sale was made to cover tax obligations arising from the release of restricted stock units, indicating it was a tax-related transaction rather than a discretionary portfolio move. Following the sale, he directly holds 336,764 shares of Lexeo common stock, which includes 252,130 restricted stock units.
LXEO notice under Rule 144 reporting proposed sale of 3,342 shares of common stock tied to restricted stock vesting on 05/15/2026. The filing also lists a prior sale of 10,173 shares by Richard N. Townsend on 02/18/2026.